<DOC>
	<DOCNO>NCT00541307</DOCNO>
	<brief_summary>The objective study collect data GORE VIABAHN Endoprosthesis Heparin Bioactive Surface treatment chronic Superficial Femoral Artery disease . Device patency 12 month primary endpoint .</brief_summary>
	<brief_title>GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface Treatment SFA Obstructive Disease ( VIPER )</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>&gt; lifestyle limit claudication , rest pain minor tissue loss &gt; ABI ( anklebrachial index ) &lt; 0.9 TBI ( toebrachial index ) &lt; 0.5 ABI &gt; 0.9 Stenosis ( &gt; 50 % ) occlusion native SFA ( superficial femoral artery ) &gt; 5cm Orifice 1 cm SFA patent Popliteal artery patent intercondylar fossa femur trifurcation At least 1 patent run vessel Guidewire deliver system successfully traverse lesion &gt; Untreated flowlimiting aortoiliac occlusive disease Any previous stenting surgery target vessel Femoral popliteal aneurysm target vessel No patent tibial artery Prior ipsilateral femoral artery bypass Major distal amputation ( transmetatarsal ) either limb Patients know sensitivity Heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
</DOC>